Holen Sie sich die Stockscreener-App
9.57
5.15%
-0.52
Handel nachbörslich:
9.54
-0.03
-0.31%
Schlusskurs vom Vortag:
$10.09
Offen:
$9.92
24-Stunden-Volumen:
114.02K
Relative Volume:
0.71
Marktkapitalisierung:
$3.24B
Einnahmen:
$417.75M
Nettoeinkommen (Verlust:
$32.27M
KGV:
98.15
EPS:
0.0975
Netto-Cashflow:
-
1W Leistung:
-6.91%
1M Leistung:
-1.24%
6M Leistung:
-41.65%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.57
$9.9705
1-Wochen-Bereich:
$9.57
$10.29
52-Wochen-Spanne:
$8.93
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Firmenname
Telix Pharmaceuticals Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
9.57 | 3.38B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-05 | Eingeleitet | Wedbush | Outperform |
| 2024-11-15 | Eingeleitet | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action InvestigationTLX - Morningstar
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
TLX Investor News: If You Have Suffered Losses in Telix - GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
About Us - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - cnhinews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX | Salt Lake City News, Weather, Sports, Breaking News | KUTV - FinancialContent
Telix stock plunges after FDA issues Complete Response Letter - Investing.com
Telix stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Telix Shares Drop After FDA Issues Complete Response Letter - MSN
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm - Barchart.com
Telix Pharmaceuticals faces SEC subpoena, investors encouraged to contact Bragar Eagel & Squire. - AInvest
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - Morningstar
Investigation into Telix Pharmaceuticals Ltd. Allegations of Misleading Business Information - AInvest
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX - Business Wire
Telix Pharmaceuticals under SEC investigation, shareholder lawsuit launched. - AInvest
Regulatory Scrutiny and Biotech Volatility: Lessons from Telix Pharmaceuticals' SEC Subpoena - AInvest
Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest
Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest
Pomerantz LLP investigates Telix Pharmaceuticals on securities fraud claims. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - FinancialContent
Telix Pharmaceuticals under investigation for potential securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Shareholders to Connect - ACCESS Newswire
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Telix Pharmaceuticals under investigation for securities fraud, ADR price falls. - AInvest
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Telix Pharmaceuticals Limited (TLX) And Encourages Investors to Connect - ACCESS Newswire
Telix Pharmaceuticals under investigation for alleged securities fraud. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Telix Announces H1 2025 Earnings Date: Global Investors Briefing Set for August 21 - Stock Titan
Telix Pharmaceuticals Limited (TLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Telix Pharmaceuticals Limited (TLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Telix Pharmaceuticals Limited (TLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Finanzdaten der Telix Pharmaceuticals Ltd Adr-Aktie (TLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):